Compare HOVR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | ACRV |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Canada | United States |
| Employees | 30 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 67.2M |
| IPO Year | N/A | 2022 |
| Metric | HOVR | ACRV |
|---|---|---|
| Price | $1.57 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.33 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 997.1K | 489.0K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.16 | $1.20 |
| 52 Week High | $4.18 | $3.56 |
| Indicator | HOVR | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 34.54 | 49.03 |
| Support Level | $1.42 | $1.62 |
| Resistance Level | $1.91 | $1.86 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 19.85 | 20.41 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.